Larotrectinib in TRK fusion–positive pediatric B-cell acute lymphoblastic leukemia

• Denis M. Schewe,
• Lennart Lenk,
• Fotini Vogiatzi,
• Dorothee Winterberg,
• Annika V. Rademacher,
• Swantje Buchmann,
• Dahlia Henry,
• Anke K. Bergmann,
• Gunnar Cario,
• Michael C. Cox

Affiliations

Denis M. Schewe

Department of Pediatrics I, Pediatric Hematology/Oncology, University Hospital Schleswig-Holstein, Kiel, Germany;; Denis M. Schewe, Department of Pediatrics I, Pediatric Hematology/Oncology, University Hospital Schleswig-Holstein, Arnold-Heller-Str 3, 24105 Kiel, Germany;

Lennart Lenk

Department of Pediatrics I, Pediatric Hematology/Oncology, University Hospital Schleswig-Holstein, Kiel, Germany;

Fotini Vogiatzi

Department of Pediatrics I, Pediatric Hematology/Oncology, University Hospital Schleswig-Holstein, Kiel, Germany;

Dorothee Winterberg

Department of Pediatrics I, Pediatric Hematology/Oncology, University Hospital Schleswig-Holstein, Kiel, Germany;

Annika V. Rademacher

Department of Pediatrics I, Pediatric Hematology/Oncology, University Hospital Schleswig-Holstein, Kiel, Germany;

Swantje Buchmann

Department of Pediatrics I, Pediatric Hematology/Oncology, University Hospital Schleswig-Holstein, Kiel, Germany;

Dahlia Henry

Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, CA

Anke K. Bergmann

Institute of Human Genetics, Medical School Hannover, Hannover, Germany

Gunnar Cario

Department of Pediatrics I, Pediatric Hematology/Oncology, University Hospital Schleswig-Holstein, Kiel, Germany;

Michael C. Cox

Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, CA